Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
Journal
BMC cancer
Journal Volume
22
Journal Issue
1
Date Issued
2022-04-09
Author(s)
El-Khoueiry, Anthony B
Meyer, Tim
Rimassa, Lorenza
Sen, Suvajit
Milwee, Steven
Kelley, Robin Kate
Abou-Alfa, Ghassan K
Abstract
Patients with hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC and Child-Pugh A liver cirrhosis at baseline, was evaluated for outcomes in patients who had Child-Pugh B cirrhosis at Week 8.
Subjects
Cabozantinib; Child–Pugh B; Hepatocellular carcinoma
Publisher
BMC
Type
journal article